IP Library Granted Patent US 9,731,002
Granted Patent B2
US 9,731,002 · App. 14/427,393 · Granted Aug 15, 2017

HIV-1 GP 120 V1/V2 antigens and immunological uses thereof

Inventors: Phillip Berman (Santa Cruz, CA); Gwen Tatsuno (Santa Cruz, CA); Bin Yu (Santa Cruz, CA); Javier Morales (Santa Cruz, CA); Kathryn Mesa (Santa Cruz, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A61K39/21A61K39/12C07K14/005C07K14/15C07K14/162C12P21/005C12N2740/16034C12N2740/16122C12N2740/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,731,002
App. No.
14/427,393
Granted
Aug 15, 2017
Kind
B2
Abstract

HIV-1 envelope proteins and fragments that possess naturally occurring and novel engineered epitopes that can be used to elicit (and are recognized by) broadly neutralizing antibodies.

Claims (10)

1. An immunogenic composition comprising an MN-rgp120 polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

2. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3.

3. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4.

4. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 5.

5. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 6.

6. The immunogenic composition of claim 1 , wherein the MN-rgp120 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 7.

7. A method for producing an MN-rgp120 polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, the method comprising expressing the MN-rgp120 polypeptide in a cell line comprising a nucleic acid encoding the MN-rgp120 polypeptide.

8. The method of claim 7 , wherein the cell line lacks N-acetylglucosaminyltransferase I (GnTI) activity.

9. A method for inducing an immune response to an MN-rgp120 polypeptide in a subject, the method comprising administering the MN-rgp120 polypeptide to the subject, where the MN-rgp120 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

10. The method of claim 9 , wherein the immune response comprises generation of broadly neutralizing antibodies that bind to the MN-rgp120 polypeptide.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF INVENTOR PHILLIP BERMAN'S NAME. PREVIOUSLY RECORDED ON REEL 035995 FRAME 0305. ASSIGNOR(S) HEREBY CONFIRMS THE SPELLING OF INVENTOR PHILLIP BERMAN'S NAME SHOULD BE CORRECTED FROM Recorded Mar 14, 2017
From: BERMAN, PHILLIP; TATSUNO, GWEN; YU, BIN; MESA, KATHRYN; MORALES, JAVIER
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 042007/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2015
From: YU, BIN; TATSUNO, GWEN; MORALES, JAVIER; MESA, KATHRYN; BERMAN, PHILIP
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 035995/0305 →
Continuity (2)
Provisional Application 61699680 · Sep 11, 2012
Related Publication 20150246111A1 · Sep 3, 2015